Table 1 Baseline characteristics of 65 AML patients with the proportion of MSCs-l available at the end of intensive chemotherapy treatment.

From: Mesenchymal stem cells-like as a prognostic biomarker in patients diagnosed with acute myeloid leukemia

  1. MSCs-l, mesenchymal stem cells-like; FAB, French American-British; ELN, European Leukemia Net.
Back to article page